Earnhardt Lisa D 4

What Happened
Lisa D. Earnhardt, EVP and Group President of Abbott Laboratories (ABT), received two compensation awards on February 24, 2026: a performance-based restricted stock award for 27,056 shares (granted at $0.00) and a derivative award covering 111,533 option-style units (granted at $0.00). These are grants/awards (code A on the Form 4), not open-market purchases or sales — they represent executive compensation, not a cash transaction.

Key Details

• Transaction date: February 24, 2026; Form 4 filed February 26, 2026 (filed within the typical 2-business-day reporting window).
• Awards: 27,056 restricted shares (performance-based RSAs) and 111,533 derivative/option units; grant price reported $0.00.
• Vesting / exercise schedule (from footnotes): the RSA is a 3-year award with no more than 1/3 vesting in any year upon Abbott reaching a minimum return-on-equity target; the option units vest/exercise in annual increments of 37,177 on 2/24/2027, 37,178 on 2/24/2028 and 37,178 on 2/24/2029.
• Tax withholding: the RSA award includes the right to have shares withheld for tax purposes.
• Rule/Exemption: the option grant was made under Abbott’s 2017 Incentive Stock Program and was reported as exempt from Section 16 liability under Rule 16b-3.
• Shares owned after the transaction: not stated in the provided filing summary.

Context
These grants are standard equity compensation: the RSAs depend on future performance targets (so they may not fully vest unless targets are met), and the option units vest over three years. Because these are awards rather than purchases or sales, they indicate compensation allocation rather than an immediate insider buy or sell signal. Any future exercises or sales of vested shares would generate additional Form 4 filings.